Corona Remedies Ltd

NSE: CORONA BSE: 544644Pharma

Incorporated in August 2004, Corona Remedies Limited is a pharmaceutical company developing, manufacturing, and marketing products in women’s healthcare, cardiology, pain management, urology, and other therapeutic areas.[1]

₹1,810

52W: ₹1337 — ₹1951

PE 55.5 · Book ₹122 · +1384% vs book

Market Cap₹11,067 Cr

Stock P/E55.5Price to Earnings

ROCE33.2%Return on Capital

ROE29.5%Return on Equity

Div. Yield0.57%Face Value ₹10

Strengths

+Company has delivered good profit growth of 23.3% CAGR over last 5 years
+Company has a good return on equity (ROE) track record: 3 Years ROE 26.5%

Weaknesses

−Stock is trading at 14.6 times its book value
−Company might be capitalizing the interest cost

Shareholding Pattern

Promoters69%

FIIs2.25%

DIIs7.02%

Public21.75%

Category	Dec 2025	Mar 2026
Promoters	69%	69%
FIIs	1.84%	2.25%▲0.4
DIIs	6.77%	7.02%▲0.3
Public	22.41%	21.75%▼0.7

Financial Statements

Metric	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Sales	314	298	294	347	361	342	353
Expenses	247	228	239	277	283	259	291
Operating Profit	67	69	54	70	78	83	62
OPM %	21%	23%	18%	20%	22%	24%	18%
Net Profit	43	45	31	46	52	41	45
EPS ₹	7.03	7.32	5.12	7.59	8.53	6.74	7.37

AI Insights

Revenue Trend

Mar 2026 revenue at ₹1,403Cr, up 17.3% YoY. OPM at 21%.

Debt Position

Borrowings at ₹165Cr. Debt-to-equity ratio: 0.24x. Healthy balance sheet.

Capex Cycle

CWIP at ₹143Cr (26% of fixed assets). Significant capex underway — growth runway building.

Margin & Efficiency

ROCE improving from 0% (Mar 2019) to 33% (Mar 2026). Working capital days: -15.

Valuation

PE 55.5x with 33.2% ROCE. Price is 1384% above book value of ₹122. Dividend yield: 0.57%.